-+ 0.00%
-+ 0.00%
-+ 0.00%

Neumora Therapeutics Says KOASTAL-2 And -3 On Track For Consolidated Topline Readout In Q2 2026; Plans To Conduct NMRA-215 Clinical Program In 2026 Following Preclinical Data From Diet Induced Obesity Model

Benzinga·01/12/2026 12:22:46
Listen to the news

Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation

KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026

Plans to conduct NMRA-215 clinical program in 2026 following class-leading preclinical data from diet induced obesity model

Advancing NMRA-511 following Phase 1b results demonstrating clinically meaningful effect on CMAI total score

Cash, cash equivalents and marketable securities expected to support operations into the third quarter of 2027

WATERTOWN, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced key pipeline updates and anticipated 2026 milestones that support the Company's mission to redefine neuroscience drug development with the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients living with brain diseases.